ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 136 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,165,883 | -44.3% | 1,914,479 | 0.0% | 0.22% | -34.7% |
| Q2 2023 | $18,244,985 | -13.4% | 1,914,479 | 0.0% | 0.33% | -19.9% |
| Q1 2023 | $21,059,269 | -42.2% | 1,914,479 | -22.2% | 0.41% | -40.7% |
| Q4 2022 | $36,409,598 | -32.0% | 2,460,108 | -12.1% | 0.70% | -29.8% |
| Q3 2022 | $53,508,000 | -47.5% | 2,800,000 | -41.4% | 0.99% | -46.2% |
| Q2 2022 | $101,897,000 | -12.9% | 4,781,646 | -21.3% | 1.85% | -2.7% |
| Q1 2022 | $116,982,000 | -7.1% | 6,073,850 | 0.0% | 1.90% | +17.2% |
| Q4 2021 | $125,972,000 | -13.2% | 6,073,850 | 0.0% | 1.62% | +1.5% |
| Q3 2021 | $145,104,000 | -12.5% | 6,073,850 | 0.0% | 1.60% | -4.9% |
| Q2 2021 | $165,755,000 | -5.7% | 6,073,850 | 0.0% | 1.68% | +2.1% |
| Q1 2021 | $175,716,000 | +2.8% | 6,073,850 | 0.0% | 1.64% | +9.9% |
| Q4 2020 | $170,857,000 | +24.8% | 6,073,850 | +30.0% | 1.50% | -13.1% |
| Q3 2020 | $136,944,000 | -3.1% | 4,673,850 | 0.0% | 1.72% | -13.5% |
| Q2 2020 | $141,337,000 | +1.5% | 4,673,850 | 0.0% | 1.99% | -15.0% |
| Q1 2020 | $139,281,000 | – | 4,673,850 | – | 2.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |